(0.14%) 5 162.00 points
(0.12%) 38 878 points
(0.11%) 18 020 points
(0.74%) $78.69
(0.61%) $2.16
(0.62%) $2 322.90
(2.29%) $27.30
(0.15%) $966.70
(0.01%) $0.929
(-0.29%) $10.84
(-0.15%) $0.796
(0.10%) $91.54
3 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 11.40%
1.42% $ 23.60
@ $29.86
Wydano: 11 kov. 2024 @ 17:11
Zwrot: -20.96%
Poprzedni sygnał: kov. 11 - 15:31
Poprzedni sygnał:
Zwrot: -1.35 %
Live Chart Being Loaded With Signals
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency...
Stats | |
---|---|
Dzisiejszy wolumen | 1.29M |
Średni wolumen | 1.48M |
Kapitalizacja rynkowa | 2.28B |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-1.350 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.35 |
ATR14 | $0.0260 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Dube Michael P | Sell | 0 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 37 966 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 54 794 | Stock Option (right to buy) |
2024-03-01 | Basta James | Buy | 32 394 | Common Stock |
2024-03-04 | Basta James | Sell | 2 297 | Common Stock |
INSIDER POWER |
---|
85.54 |
Last 100 transactions |
Buy: 1 561 723 | Sell: 123 854 |
Wolumen Korelacja
Intellia Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
PYCR | 0.85 |
NVIV | 0.838 |
RKDA | 0.833 |
BIOC | 0.826 |
LAZY | 0.822 |
CDZI | 0.82 |
HUGE | 0.818 |
SBUX | 0.818 |
TNXP | 0.806 |
RGP | 0.804 |
10 Najbardziej negatywne korelacje | |
---|---|
UIHC | -0.813 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Intellia Therapeutics Inc Korelacja - Waluta/Towar
Intellia Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $36.28M |
Zysk brutto: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2023 |
Przychody: | $36.28M |
Zysk brutto: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2022 |
Przychody: | $52.12M |
Zysk brutto: | $44.55M (85.47 %) |
EPS: | $-6.37 |
FY | 2021 |
Przychody: | $33.05M |
Zysk brutto: | $33.05M (100.00 %) |
EPS: | $-3.78 |
Financial Reports:
No articles found.
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej